NEW YORK (GenomeWeb News) – Foundation Medicine today said that it has signed a multi-year alliance with Eisai to conduct genomic profiling and diagnostic discovery for an oncology therapeutic candidate being developed by the Japanese drug firm.

The Cambridge, Mass.-based firm said that the goal of the collaboration is to prospectively identify specific genomic alterations in each patient's tumor. The results would be used for patient stratification, for guiding further drug development, and potentially for the commercialization of molecular diagnostic products.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The American Society of Human Genetics has issued a position statement on genetic testing of children.

The White House seeks to update how biotechnology products are regulated.

Team science leads some researchers to get lost in the shuffle, the Chronicle of Higher Education reports.

In PLOS this week: oral microbiomes of dogs and their owners, Plasmodium vivax population structure, and more.